Skip Nav Destination
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis
False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy
Issue Archive
Table of Contents
BLOOD COMMENTARIES
PLENARY PAPER
TRANSPLANTATION
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Clinical Trials & Observations
Rizwan Romee,Sarah Cooley,Melissa M. Berrien-Elliott,Peter Westervelt,Michael R. Verneris,John E. Wagner,Daniel J. Weisdorf,Bruce R. Blazar,Celalettin Ustun,Todd E. DeFor,Sithara Vivek,Lindsey Peck,John F. DiPersio,Amanda F. Cashen,Rachel Kyllo,Amy Musiek,András Schaffer,Milan J. Anadkat,Ilana Rosman,Daniel Miller,Jack O. Egan,Emily K. Jeng,Amy Rock,Hing C. Wong,Todd A. Fehniger,Jeffrey S. Miller
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis
Clinical Trials & Observations
Geffen Kleinstern,Nicola J. Camp,Lynn R. Goldin,Celine M. Vachon,Claire M. Vajdic,Silvia de Sanjose,J. Brice Weinberg,Yolanda Benavente,Delphine Casabonne,Mark Liebow,Alexandra Nieters,Henrik Hjalgrim,Mads Melbye,Bengt Glimelius,Hans-Olov Adami,Paolo Boffetta,Paul Brennan,Marc Maynadie,James McKay,Pier Luigi Cocco,Tait D. Shanafelt,Timothy G. Call,Aaron D. Norman,Curtis Hanson,Dennis Robinson,Kari G. Chaffee,Angela R. Brooks-Wilson,Alain Monnereau,Jacqueline Clavel,Martha Glenn,Karen Curtin,Lucia Conde,Paige M. Bracci,Lindsay M. Morton,Wendy Cozen,Richard K. Severson,Stephen J. Chanock,John J. Spinelli,James B. Johnston,Nathaniel Rothman,Christine F. Skibola,Jose F. Leis,Neil E. Kay,Karin E. Smedby,Sonja I. Berndt,James R. Cerhan,Neil Caporaso,Susan L. Slager
LYMPHOID NEOPLASIA
Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma
Hiroshi Higuchi,Natsuko Yamakawa,Ken-Ichi Imadome,Takashi Yahata,Ryutaro Kotaki,Jun Ogata,Masatoshi Kakizaki,Koji Fujita,Jun Lu,Kazuaki Yokoyama,Kazuki Okuyama,Ai Sato,Masako Takamatsu,Natsumi Kurosaki,Syakira Mohamad Alba,Azran Azhim,Ryouichi Horie,Toshiki Watanabe,Toshio Kitamura,Kiyoshi Ando,Takao Kashiwagi,Toshimitsu Matsui,Akinao Okamoto,Hiroshi Handa,Masahiko Kuroda,Naoya Nakamura,Ai Kotani
RED CELLS, IRON, AND ERYTHROPOIESIS
TRANSFUSION MEDICINE
LETTERS TO BLOOD
False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy
Clinical Trials & Observations
Theodore W. Laetsch,Shannon L. Maude,Michael C. Milone,Kara L. Davis,Joerg Krueger,Ana Maria Cardenas,Lamis K. Eldjerou,Christopher H. Keir,Patricia A. Wood,Stephan A. Grupp
BLOOD WORK
-
Cover Image
Cover Image
First-in-human weekly treatment with the IL-15 superagonist complex ALT-803 induces expansion and activation of natural killer cells and CD8+ T cells in patients who relapse after allogeneic hematopoietic cell transplantation. Shown on the cover is an injection site reaction showing a predominant γδ T-cell infiltrate induced by ALT-803. See the article by Romee et al on page 2515.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals